ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
Syncom Formulations' promoters have voluntarily waived their right to the proposed final dividend of ₹0.10 per share. This waiver reduces total dividend payout obligations.
Syncom Formulations fixed 23 Sep 2026 as record date for a proposed 10% dividend (Rs.0.10/share) pending AGM approval. The 38th AGM is scheduled for 30 Sep 2026.
Syncom Formulations (India) Limited informed exchanges about the dispatch of letters to shareholders with unregistered email addresses, providing instructions to access the 38th AGM Notice and Annual Report.
Syncom Formulations appointed M/s M. Goyal & Co. as Cost Auditor and M/s Bansal & Agrawal as Internal Auditor for FY 2026-27.
Syncom Formulations India Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulations.
Syncom Formulations (India) Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory adherence.
Syncom Formulations (India) Ltd submitted its compliance certificate under Regulation 74(5) of SEBI Regulations for the quarter ended March 31, 2026. The certificate confirms that security certificates received for dematerialization were processed, mutilated, and cancelled as per regulatory requirements by their Registrar, Ankit Consultancy Pvt. Ltd.
Promoters of Syncom Formulations (India) Limited, including Kedarmal and Vijay Shankarlal Bankda, submitted their annual declaration under SEBI SAST Regulations for FY 2025-26. They confirmed no new encumbrances were made on their shareholding during the year, maintaining transparency in promoter-level security interests.